\n
\n
\n Date
\n Event
\n Sentiment
\n Move
\n Catalyst
\n
\n
\n
\n
\n
\n Apr 17
\n
\n
\n Board appointment<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n -0.2%
\n
\n
\n
\n
\n
\n Independent ex-EY partner added to board and key committees.
\n
\n
\n
\n
\n Feb 23
\n
\n
\n Clinical data update<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +2.3%
\n
\n
\n
\n Published safety and tolerability data for autologous NK cell infusions.
\n
\n
\n
\n
\n Jan 30
\n
\n
\n Pipeline expansion<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +4.3%
\n
\n
\n
\n Announced potential exosome pipeline expansion beyond CELESOME(+).
\n
\n
\n
\n
\n Jan 08
\n
\n
\n CFO appointment<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +2.0%
\n
\n
\n
\n Named new CFO with extensive finance and accounting experience.
\n
\n
\n
\n <\/p>\n
Pattern Detected<\/p>\n
Recent corporate and clinical updates with generally positive tone saw mixed immediate price reactions, with one governance update drawing a slight negative move.<\/p>\n
Recent Company History<\/p>\n
Over the past months, Alps Group reported several governance and pipeline developments. Board and CFO appointments in January 2026 and April 2026 aimed at strengthening financial oversight, while clinical and pipeline updates in January and February 2026 highlighted early-stage NK cell and exosome work. Price reactions to these otherwise constructive announcements ranged from about flat to modestly positive, suggesting that prior news did not consistently trigger strong directional moves, in contrast to the more clearly risk-focused Nasdaq deficiency notice.<\/p>\n
\n This announcement highlights that Alps Group fell below Nasdaq\u2019s $1.00 minimum bid requirement over 30 consecutive business days and now faces a 180-day window, until November 11, 2026, to regain compliance. Historically, the company has focused on governance upgrades and early-stage clinical progress. Investors may watch how management addresses potential actions such as a reverse split, alongside execution on its biotech and wellness platform, to manage ongoing listing and financing risks.
\n <\/p>\n
\n
\n nasdaq listing rules 5450(a)(1)
\n
\n regulatory
\n
\n
<\/p>\n
“under Nasdaq Listing Rules 5450(a)(1), which requires the Company to maintain”<\/p>\n
Nasdaq Listing Rule 5450(a)(1) is a stock exchange standard that requires a listed company’s shares to maintain a minimum trading bid price (commonly $1.00) to remain on the exchange. It matters to investors because falling below that floor can trigger a warning and possible delisting, similar to a store losing its lease if it no longer meets a mall\u2019s rent rules\u2014affecting liquidity, valuation and the ease of buying or selling the stock.<\/p>\n
<\/p>\n
\n
\n minimum bid price
\n
\n regulatory
\n
\n
<\/p>\n
“to maintain a minimum bid price of $1.00 per share”<\/p>\n
The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction\u2014think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.<\/p>\n
<\/p>\n
\n
\n reverse stock split
\n
\n financial
\n
\n
<\/p>\n
“by effecting a reverse stock split, if necessary”<\/p>\n
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.<\/p>\n
<\/p>\n
\n
\n delisting
\n
\n regulatory
\n
\n
<\/p>\n
“Nasdaq will provide notice that the Company\u2019s securities will be subject to delisting”<\/p>\n
Delisting occurs when a company’s stock is removed from a stock exchange and is no longer available for trading there. This can happen voluntarily or because the company no longer meets the exchange’s requirements. For investors, delisting means they can no longer buy or sell shares of that company on the exchange, which may make it more difficult to sell their investments or affect the stock’s value.<\/p>\n
<\/p>\n
AI-generated analysis. Not financial advice.<\/p>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n 05\/19\/2026 – 04:05 PM
\n
\n
<\/p>\n
KUALA LUMPUR, Malaysia, May 19, 2026 (GLOBE NEWSWIRE) — Alps Group Inc (the \u201cCompany\u201d or \u201cAlps Group\u201d), the parent company of Alps Life Sciences Inc. (\u201cAlps Holdco\u201d), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced that on May 15, 2026, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (\u201cNasdaq\u201d) notifying the Company that based on the closing bid price of the ordinary shares of the Company for the last 30 consecutive business days, the Company is currently not in compliance with the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(a)(1), which requires the Company to maintain a minimum bid price of $1.00 per share.<\/p>\n
The notification has no immediate effect on the listing or trading of the Company\u2019s ordinary shares on Nasdaq, and it does not affect the Company\u2019s current business operations or financial condition. Nasdaq has provided the Company with a compliance period of 180 calendar days, or until November 11, 2026, in which to regain compliance with Nasdaq continued listing requirement. In the event that the Company does not regain compliance in the compliance period, the Company may be eligible for an additional 180 calendar days, should the Company meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and is able to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company\u2019s securities will be subject to delisting.<\/p>\n
The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq\u2019s continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance, there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.<\/p>\n
About Alps Group<\/p>\n
Alps Group Inc is the parent company of Alps Life Sciences Inc., an integrated biotechnology platform integrating research and development, medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes globally. Alps Group\u2019s mission is to create a fair healthcare ecosystem, to make advance predictive, preventive, and precision medicine accessible and affordable.<\/p>\n
Forward-Looking Statements<\/p>\n
Certain statements in this press release may be considered to contain certain \u201cforward-looking statements\u201d within the meaning of \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: \u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cwill,\u201d \u201cshall,\u201d \u201cmay,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cwould,\u201d \u201cpositioned,\u201d \u201cfuture,\u201d \u201cforecast,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cproject\u201d and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company management\u2019s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.<\/p>\n
A further list and description of risks and uncertainties can be found in documents filed with the Securities and Exchange Commission (\u201cSEC\u201d) by the Company and other documents that we may file or furnish with the SEC, which you are encouraged to read. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.<\/p>\n
Investor Relations Contact
Philip Carlson
KCSA Strategic Communications
212-896-1233
alps@kcsa.com<\/p>\n
![\"\"](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/05\/Alps-Group-Inc.png\")
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
<\/p>\n
\n FAQ
\n <\/p>\n
\n
\n
<\/p>\n
What Nasdaq notification did Alps Group (Nasdaq:ALPS) receive on May 15, 2026?<\/p>\n
\n Alps Group received a Nasdaq notice that it is not compliant with the $1.00 minimum bid price rule. According to the company, the stock traded below $1.00 for 30 consecutive business days, triggering a minimum bid price deficiency under Nasdaq Listing Rule 5450(a)(1).
\n <\/p>\n
\n
<\/p>\n
How long does Alps Group (ALPS) have to regain Nasdaq minimum bid price compliance?<\/p>\n
\n Alps Group has an initial 180-day compliance period, ending November 11, 2026, to restore its bid price. According to the company, it may qualify for a second 180-day period if other initial listing standards, excluding bid price, are met and plans to cure are provided.
\n <\/p>\n
\n
<\/p>\n
Does the Nasdaq bid price deficiency notice affect Alps Group (ALPS) trading or operations?<\/p>\n
\n The Nasdaq notice has no immediate effect on Alps Group\u2019s listing, trading, operations, or financial condition. According to the company, its ordinary shares continue trading on Nasdaq while it evaluates options and works toward regaining compliance with the minimum bid price requirement.
\n <\/p>\n
\n
<\/p>\n
Could Alps Group (ALPS) be delisted from Nasdaq due to the minimum bid price deficiency?<\/p>\n
\n Yes, delisting is possible if Alps Group cannot regain compliance within allowed periods. According to the company, Nasdaq may move to delist if the deficiency is not cured or the company fails to meet other initial listing standards required for an additional compliance period.
\n <\/p>\n
\n
<\/p>\n
What actions might Alps Group (ALPS) take to fix its Nasdaq bid price deficiency?<\/p>\n
\n Alps Group is evaluating options and may consider a reverse stock split if needed. According to the company, it intends to use reasonable efforts to regain Nasdaq bid price compliance but cannot assure success or ongoing compliance with all continued listing requirements.
\n <\/p>\n
\n
\n
\n
\n
\n
\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
Alps Group (Nasdaq:ALPS) received a Nasdaq notice on May 15, 2026 for not…\n","protected":false},"author":2,"featured_media":68441,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[16],"tags":[50,15288,336,36917,36916,36915,2929,25421],"class_list":["post-68440","post","type-post","status-publish","format-standard","has-post-thumbnail","category-alps","tag-alps","tag-alps-group","tag-biotechnology","tag-delisting","tag-listing-compliance","tag-minimum-bid-price","tag-nasdaq","tag-stock-price"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116603262400839879","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/68440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=68440"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/68440\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/68441"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=68440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=68440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=68440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}